Seasoned Commercial Leader with Track Record in Life Sciences and Diagnostics
SOUTH SAN FRANCISCO, Calif., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced the appointment of Jonathan Day as Vice President, Commercial Operations, Americas.
Day will be responsible for leading all commercial activities in the Americas, furthering market adoption of Fluidigm products, particularly in the growing scientific community studying the human immune system. He reports to Colin McCracken, Chief Commercial Officer.
Day was most recently Vice President, Sales and Support, Americas, for Agena Bioscience. At Agena, Day significantly grew revenues for its mass spectrometry platform, which has applications in cancer profiling for solid tumors and liquid biopsies; in inherited genetic disease testing, including carrier screening; and in pharmacogenetics, sample integrity solutions and clinical research.
Previously, he held roles of increasing responsibility at Thermo Fisher Scientific, where he drove sales for next-generation sequencing technologies and quantitative and digital PCR products in markets that included oncology and public health, as well as niche applications and workflows. Earlier in his career, at Affymetrix, he worked to expand large-pharma adoption of that company’s microarray technologies in translational sciences, clinical pharmacogenetics and biomarker discovery and development programs.
“We are thrilled to welcome a commercial leader of Jonathan’s caliber to the team,” said McCracken. “I am confident he will drive for results in the critical U.S. market, where our mass cytometry customer base is rapidly branching beyond the top-tier research centers as pharma customers increasingly adopt our technology.”
“Fluidigm’s products are unlocking tremendous scientific value and long-term health care insights,” said Day. “I am very excited for the opportunity to help grow the business and deliver this extraordinary technology into the hands of more customers in the U.S. market.”
Fluidigm (NASDAQ:FLDM) is an industry-leading biotechnology tools provider with a vision to improve life through comprehensive health insight. We focus on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF® and microfluidics technologies, we develop, manufacture, and market multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, and plant and animal research laboratories worldwide. Together with them, we strive to increase the quality of life for all. For more information, visit fluidigm.com.
Fluidigm, the Fluidigm logo, and CyTOF are trademarks and/or registered trademarks of Fluidigm Corporation in the United States and/or other countries. All other trademarks are the sole property of their respective owners. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.
Senior Director, Corporate Communications
650 243 6621
Vice President, Investor Relations
650 416 7423
Source: Fluidigm Corporation